BRCA1 Mutation, BRCA2 Mutation, Chinese, Epithelial Ovarian Cancer, Homologous Recombination Deficiency, Homologous Recombination Genes, Prognosis
Conditions
Brief summary
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known. This study would recruit 400 Chinese EOC patients with known targeted gene mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.
Interventions
GENETICEvaluation of homologous recombination deficiency score
Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
Sponsors
Lei Li
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
* Aged 18 years or older * Pathological confirmation of epithelial ovarian cancer * With available tumor tissues * Given consents to participate the study
Exclusion criteria
* Not meeting all of the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Homologous recombination deficiency (HRD) score | Two years | The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for three types of important molecular mechanism: loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Five years | Overall survival in recruited patients |
| Progression-free survival | Five years | Progression-free survival in recruited patients |
Countries
China
Outcome results
None listed